ReCode Therapeutics is a biopharmaceutical company developing precision medicines for genetic respiratory diseases with significant unmet medical need.
ReCode’s diverse pipeline includes lead programs for primary ciliary dyskinesia (PCD) and nonsense mutations in cystic fibrosis (CF).
ReCode Therapeutics was founded in 2015 by Daniel Siegwart, Philip Thomas, and Michael Torres. The company is headquartered in Dallas, Texas.
Recode's proprietary non-viral lipid nanoparticle platform enables the delivery of a variety of payloads, and precise organ targeting of nucleic acid and protein payloads via both systemic and local delivery.
ReCode is leveraging its nanoparticle and nucleic acid technologies across multiple modalities, including mRNA-mediated protein replacement therapies, first-in-class tRNA NanoCorrectors for diseases caused by nonsense mutations, and gene editing.
ReCode Therapeutics is backed by OrbiMed Advisors, Colt Ventures, MPM Capital, Vida Ventures LLC, Hunt Technology Ventures and others. The company raised $80M in a Series A round on Mar 26, 2020. This brings ReCode's total funding to $84M to date.